Factor Xii
Mostrando 1-12 de 74 artigos, teses e dissertações.
-
1. Avaliação do efeito de contraceptivos hormonais sobre o sistema complemento / Evaluation of the effect of hormonal contraceptives on the complement system
The occurrence of thrombosis is often associated with the presence of one or more risk factors, which may be genetic and/or acquired, such as hormonal changes that occur during pregnancy, hormone replacement therapy and the use of combined hormonal contraceptives (CHC). The inflammation in turn, is an important body\ s response to the aggression and involves
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 29/04/2011
-
2. Planejamento e síntese de intermediários para a obtenção de novos candidatos a protótipos de fármacos anticoagulantes desenhados a partir da infestina-4 / Planning and synthesis of intermediates for obtaining new candidates for prototypes of anticoagulants drawn from the infestin-4
Thromboembolic disorders produce the majority of diseases affecting the heart, and are the third leading cause of death worldwide. Venous thromboembolism is a thromboembolic disorder that occurs in the venous circulation, is a disease of high prevalence and remains a major cause of morbidity and mortality in hospitalized patients undergoing major surgery, th
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 15/09/2010
-
3. Planejamento e síntese de intermediários para a obtenção de novos candidatos a protótipos de fármacos anticoagulantes desenhados a partir da infestina-4 / Planning and synthesis of intermediates for obtaining new candidates for prototypes of anticoagulants drawn from the infestin-4
As desordens tromboembólicas geram a maioria das doenças que acometem o coração, e são a terceira causa de morte mundial. O tromboembolismo venoso é uma desordem tromboembólica que ocorre na circulação venosa, é uma enfermidade de alta prevalência e continua sendo uma causa importante de morbimortalidade em pacientes hospitalizados e submetidos a
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 15/09/2010
-
4. Cardioprotective effect of ornitho-kinin in an anesthetized, open-chest chicken model of acute coronary occlusion
The generation of bradykinin (BK; Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) in blood and kallidin (Lys-BK) in tissues by the action of the kallikrein-kinin system has received little attention in non-mammalian vertebrates. In mammals, kallidin can be generated by the coronary endothelium and myocytes in response to ischemia, mediating cardioprotective events. The
Brazilian Journal of Medical and Biological Research. Publicado em: 2009-09
-
5. Glycosaminoglycans affect the interaction of human plasma kallikrein with plasminogen, factor XII and inhibitors
Human plasma kallikrein, a serine proteinase, plays a key role in intrinsic blood clotting, in the kallikrein-kinin system, and in fibrinolysis. The proteolytic enzymes involved in these processes are usually controlled by specific inhibitors and may be influenced by several factors including glycosaminoglycans, as recently demonstrated by our group. The aim
Brazilian Journal of Medical and Biological Research. Publicado em: 2003-08
-
6. Structure-activity relationship of synthetic peptides derived from human acidic Fibroblast Growth Factor Site 2 primary sequence / Peptídeos de conformação restrita relacionados ao sítio 2 do fator de crescimento de fibroblastos ácido humano (hFGF-1): estudo sobre estrutura e atividade
Na busca por agonistas, antagonistas e inibidores de natureza peptídica do fator de crescimento de fibroblastos ácido humano (hFGF-1), iniciamos o presente trabalho fazendo uma análise conformacional teórica do peptídeo Ac- WFVGLKKNGSSKRGPRT-NH2 (107-123 [hFGF-1]). Em trabalho anterior, este composto havia se mostrado um agonista da atividade mitogênic
Publicado em: 2000
-
7. Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells.
The structure of coagulation factor XII (Hageman factor), inferred from its DNA sequence, includes two epidermal growth factor (EGF)-homologous domains in its amino-terminal region. This suggests that factor XII may exhibit EGF-like activities. Reciprocal antigenic cross-reactivity between factor XII and EGF was shown by exposing purified human factor XII or
-
8. Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase.
Clotting factor XII (Hageman factor) contains epidermal growth factor (EGF)-homologous domains and is reported to be a potent mitogen for human hepatoma (HepG2) cells. In this study, we tested whether factor XII exhibits growth factor activity on several other EGF-sensitive target cells, including fetal hepatocytes, endothelial cells, alveolar type II cells,
-
9. Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571----Ser substitution.
Structural studies on a congenital abnormal coagulation factor XII (Hageman factor), factor XII Washington D.C., have been performed to identify the defect responsible for its lack of procoagulant activity. Amino acid sequence analysis of a tryptic peptide isolated from the abnormal factor XII indicated that Cys-571 (equivalent to Cys-220 in the chymotrypsin
-
10. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo.
In this study the contribution of activation of the contact system to activation of the fibrinolytic system in vivo was investigated in healthy volunteers and in factor XII deficient patients. The plasminogen activating activity in plasma from healthy volunteers after infusion of desamino D-arginine vasopressin (DDAVP) was only partially blocked (for 77%) wi
-
11. Factor XI contributes to thrombin generation in the absence of factor XII
During surface-initiated blood coagulation in vitro, activated factor XII (fXIIa) converts factor XI (fXI) to fXIa. Whereas fXI deficiency is associated with a hemorrhagic disorder, factor XII deficiency is not, suggesting that fXI can be activated by other mechanisms in vivo. Thrombin activates fXI, and several studies suggest that fXI promotes coagulation
American Society of Hematology.
-
12. Activation of factor XII-dependent pathways in human plasma by hematin and protoporphyrin.
Intravenous administration of hematin is effective in the treatment of acute exacerbations of the inducible porphyrias. In the course of such treatment, coagulopathies have occurred that are characterized by prolongation of prothrombin time, partial thromboplastin time, and formation of fibrin split products. In experiments in vitro with normal human plasma,